Skip to main content

Antiviral monoclonal antibody therapy for COVID-19 – does it work?

Monoclonal antibodies are used to treat a variety of conditions from cancer to autoimmune disorders. The most well-known monoclonal antibody therapy for an infectious disease is a drug called ZMapp. Targeting Ebola virus, ZMapp is a combination of three monoclonal antibodies approved for use in 2014 during the largest Ebola outbreak in West Africa. Early in the COVID-19 pandemic, several companies started developing monoclonal antibodies directed against another deadly virus, SARS-CoV-2.


How monoclonal antibodies work

During an immune response, B cells (also called B lymphocytes) make antibodies that target the pathogen. Many B cells participate in this response, producing a large mix of antibodies that bind to different regions of the pathogen in a process known as neutralization — essentially coating the pathogen to block it from infecting cells. A primary goal of vaccination is to elicit neutralizing antibodies to block the pathogen from infecting cells, thereby protecting vaccinated individuals from infection.

The antibodies that the body makes in response to infection or vaccination targeting different sites on the pathogen are referred to as polyclonal antibodies. In contrast, monoclonal antibodies, which are made in a lab, target just one specific part of the pathogen. Antiviral monoclonal antibodies can still neutralize the pathogen if their target is the protein that the pathogen uses to infect cells. For SARS-CoV-2, this is the spike protein.


Therapies authorized for COVID-19

To date, four monoclonal antibodies targeting the SARS-CoV-2 spike protein have been authorized for use in the United States, and one in Canada, to treat high-risk outpatients who have mild-to-moderate disease with the goal of preventing progression to severe disease. These four monoclonal antibodies are called bamlanivimab (authorized in Canada), etesevimab, casirivimab, and imdevimab. In addition to being nearly impossible to pronounce, monoclonal antibodies contain the suffix “mab” for monclonal antibody.


Evidence on efficacy

Therapy is given as an intravenous infusion, most often delivered at an infusion center in health care facilities with immediate access to mediations to treat severe reactions should they occur. The rationale for outpatient therapy is that once patients are sick enough to require hospitalization, the immune response is already making its own antibodies to fight the infection and adding more is not likely to be beneficial. Demonstrating that point, the ACTIV-3 trial showed that bamlanivimab did not improve recovery in hospitalized patients with COVID-19.

To the contrary, since outpatients may be in an earlier phase of infection, antiviral monoclonal antibody therapy may be effective at slowing viral replication and preventing progression to severe disease. Combination therapy of bamlanivimab plus etesevimab, or casirivimab plus imdevimab, reduced SARS-CoV-2 viral load in patients with mild-to-moderate COVID-19 in the BLAZE-1 trial and REGN-COV2 trial, respectively. While therapy reduced the amount of SARS-CoV-2 virus in patients, bamlanivimab plus etesevimab did not lessen symptoms or speed time to recovery, and these clinical outcomes were not evaluated in the other trial. However, bamlanivimab plus etesevimab did reduce COVID-19-related medical visits (0.9% with therapy compared to 5.8% with placebo, p = 0.049), though casirivimab plus imdevimab did not significantly reduce medical visits (3% with therapy compared to 6% with placebo). Together, these studies suggest that monoclonal antibody therapy may help to expedite SARS-CoV-2 viral clearance in patients with mild-to-moderate illness, which does not appear to impact symptoms but might reduce the need for medical visits and alleviate strain on health care systems.


Challenges of monoclonal antibody therapy

Beyond efficacy, there are logistical challenges to monoclonal antibody therapy. First, the high cost of drug development and time-consuming manufacturing process have contributed to limited supply.

Second, treatment and monitoring largely occurs at specialized infusion centers, which are not available at all health care facilities and may not be accessible to those who live far away or who have limited transportation. Altogether these challenges result in inequitable delivery of monoclonal antibody therapy, potentially compounding existing socioeconomic disparities already exacerbated by the pandemic.

Furthermore, treating patients with mild-to-moderate COVID-19 in an outpatient facility increases the risk of transmission at a time when they may be most infectious. Considering that infusion centers also often treat immunosuppressed individuals (such as people with cancer receiving chemotherapy), the risk of transmission to others is not insignificant.

Because antiviral monoclonal antibody therapy appears to be more effective early in disease course, it is also being tested as postexposure prophylaxis for healthy people who have been exposed to someone with COVID-19. Regeneron has reported positive interim results for postexposure prophylaxis in a press release, potentially paving the way for this indication. However, as vaccination coverage increases globally, the need for prophylaxis will undoubtedly wane.


Bottom line

So, does antiviral monoclonal antibody therapy work? Measured in viral load, it appears effective. However, clinical outcomes are modest and likely only beneficial to patients at highest risk of progression during a short window early after illness onset. Taken together, along with the many barriers to administration, monoclonal antibody therapy has had limited utility for COVID-19.

For more information, see the topic COVID-19 (Novel Coronavirus) in DynaMed

Original article published on EBSCO Health Notes. Written by:

  • Vito Iacoviello, MD, Deputy Editor for Infectious Disease, Allergy, and Immunology at DynaMed; and
  • Heather D. Marshall, PhD, Senior Medical Writer in Infectious Disease, Allergy, and Immunology and Digital Media Specialist at DynaMed.

CMA members have access to DynaMed, a point-of-care reference tool valued at US$399 per year, as part of their membership.

Do you have a question on COVID-19 or another clinical topic? Contact the Ask a Librarian team to request a literature search.


This material is for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. The opinions stated by the authors are made in a personal capacity and do not necessarily reflect those of the Canadian Medical Association and its subsidiaries including Joule. 

About the author(s)

DynaMed is a clinician-focused tool designed to facilitate efficient and evidence-based patient care. Rigorous, daily review of medical literature by physician and specialist staff ensures timely and objective analysis, synthesis and guidance. DynaMed includes drug content from Micromedex, Canadian and international guidelines, and clinical images. CMA members have access to DynaMed, a point-of-care tool, included with their membership ― a tool valued at US$399 a year.